570 related articles for article (PubMed ID: 29195073)
21. Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer.
Bauer C; Kühnemuth B; Duewell P; Ormanns S; Gress T; Schnurr M
Cancer Lett; 2016 Oct; 381(1):259-68. PubMed ID: 26968250
[TBL] [Abstract][Full Text] [Related]
22. Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphoma.
Tiper IV; Webb TJ
Cancer Immunol Immunother; 2016 Nov; 65(11):1411-1421. PubMed ID: 27614429
[TBL] [Abstract][Full Text] [Related]
23. DNMT inhibitors and HDAC inhibitors regulate E-cadherin and Bcl-2 expression in endometrial carcinoma in vitro and in vivo.
Yi TZ; Li J; Han X; Guo J; Qu Q; Guo L; Sun HD; Tan WH
Chemotherapy; 2012; 58(1):19-29. PubMed ID: 22343305
[TBL] [Abstract][Full Text] [Related]
24. Immune checkpoint modulation for non-small cell lung cancer.
Soria JC; Marabelle A; Brahmer JR; Gettinger S
Clin Cancer Res; 2015 May; 21(10):2256-62. PubMed ID: 25979932
[TBL] [Abstract][Full Text] [Related]
25. EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion.
Marzio A; Kurz E; Sahni JM; Di Feo G; Puccini J; Jiang S; Hirsch CA; Arbini AA; Wu WL; Pass HI; Bar-Sagi D; Papagiannakopoulos T; Pagano M
Cell; 2022 Jan; 185(1):169-183.e19. PubMed ID: 34963055
[TBL] [Abstract][Full Text] [Related]
26. Advances in Immuno-Oncology: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer-Introduction.
Socinski MA
Semin Oncol; 2015 Oct; 42 Suppl 2():S1-2. PubMed ID: 26477469
[No Abstract] [Full Text] [Related]
27. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.
Anagnostou VK; Brahmer JR
Clin Cancer Res; 2015 Mar; 21(5):976-84. PubMed ID: 25733707
[TBL] [Abstract][Full Text] [Related]
28. Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines.
Hanke NT; Garland LL; Baker AF
J Cancer Res Clin Oncol; 2016 Mar; 142(3):549-60. PubMed ID: 26385374
[TBL] [Abstract][Full Text] [Related]
29. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
Zhong S; Fields CR; Su N; Pan YX; Robertson KD
Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
[TBL] [Abstract][Full Text] [Related]
30. [Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer].
Wang S; Li J
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):682-686. PubMed ID: 27760599
[TBL] [Abstract][Full Text] [Related]
31. The Combination of New Immunotherapy and Radiotherapy: A N ew Potential Treatment for Locally Advanced Non-Small Cell Lung Cancer.
Sacco PC; Maione P; Guida C; Gridelli C
Curr Clin Pharmacol; 2017; 12(1):4-10. PubMed ID: 27908252
[TBL] [Abstract][Full Text] [Related]
32. Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications.
Gray SG; Al-Sarraf N; Baird AM; Cathcart MC; McGovern E; O'Byrne KJ
Eur J Cancer; 2009 Nov; 45(17):3087-97. PubMed ID: 19818596
[TBL] [Abstract][Full Text] [Related]
33. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
34. A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study.
Yang YJ; Park JC; Kim HK; Kang JH; Park SY
Anticancer Res; 2013 May; 33(5):2115-22. PubMed ID: 23645763
[TBL] [Abstract][Full Text] [Related]
35. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells.
Komatsu N; Kawamata N; Takeuchi S; Yin D; Chien W; Miller CW; Koeffler HP
Oncol Rep; 2006 Jan; 15(1):187-91. PubMed ID: 16328054
[TBL] [Abstract][Full Text] [Related]
36. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.
Santana-Davila R; Chow LQ
Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785
[No Abstract] [Full Text] [Related]
37. [Non-small cell lung cancer: news from immunotherapy].
Reinmuth N; Heigener DF; Reck M
Dtsch Med Wochenschr; 2015 Mar; 140(5):329-33. PubMed ID: 25734674
[TBL] [Abstract][Full Text] [Related]
38. Harnessing the immune system for the treatment of non-small-cell lung cancer.
Brahmer JR
J Clin Oncol; 2013 Mar; 31(8):1021-8. PubMed ID: 23401435
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future.
Steendam CM; Dammeijer F; Aerts JGJV; Cornelissen R
Immunotherapy; 2017 May; 9(6):507-520. PubMed ID: 28472903
[TBL] [Abstract][Full Text] [Related]
40. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]